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Modification of chicken liver fructose-1,6-
bisphosphatase with butanedione in borate buffer (pH 8.1)
leads to desensitization of the enzyme to inhibition by AMP
and fructose-2,6-bisphosphate. Desensitization to AMP
inhibition can be prevented if modification is carried out
in the presence of AMP, while fructose-1,6-bisphosphate and
fructose-2,6-bisphosphate can protect the enzyme against
desensitization to inhibition by fructose-2,6-bisphosphate.
Since butanedione is a reagent highly specific for
modification of arginine in proteins, it is considered that
arginine may be present at both the AMP and fructose 2,6-
bisphosphate sites.
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Fructose-l,6-bisphosphatase (FBPase) (EC 3.1.3.11), the
enzyme that catalyzes the hydrolysis of D-fructose-1,6-
bisphosphate to fructose-6-phosphate and phosphate(Pi), was
first discovered in rabbit liver by Gomori in 1943.1 This
enzyme has since been shown to play a key role in
gluconeogenesis.2 FBPase is necessary for the formation of
glucose from fructose, lactate, glycerol, and gluconeogenic
amino acids.3 One defect in this enzyme system results in
impairment in the gluconeogenic process. It has been
reported that bacterial mutants lacking FBpase were unable
to grow on compounds such as glycerol, acetate, or succinate
as carbon sources.4 In humans, the metabolic disorder known
as "infantile lactic acidosis" has been found to be
associated with hepatic FBPase deficiency.5~8
The native "neutral pH optimum" FBPases isolated from
different sources are tetramers composed of identical
subunits of molecular weights ranging from about 36,000 to
40,000.9"12 A common feature of FBPase from various sources
appears to be the presence of four highly reactive
sulfhydryl (SH) groups per molecule of enzyme.13 FBPases
from all known sources require a divalent cation (Mg2+ or
Mn2+) for activity.2 FBPases from most sources are
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activated by K+ or NH4+ 14 and inhibited by Zn2+,15"18
AMP,2'19 fructose-2,6-bisphosphate,20 and high concen
trations of substrate.2'21'22
The inhibition of this enzyme by AMP is allosteric
in nature.19 This inhibition can be totally or nearly
totally abolished by treatment with butanedione,23'24
acetylimidazole,25 pyridoxal-phosphate,26"29 and
acetylsalicylate,30 suggesting that arginyl, tyrosyl,
and lysyl residues are all present at the AMP allosteric
site.23"29 Han et al31 have recently found that
acetylsalicylate and pyridoxal-phosphate alter the AMP
allosteric property of turkey liver FBPase by modifying
the same lysyl residues at the AMP site.
Most researchers believe that fructose-2,6-bisphosphate
inhibits FBPase by binding at the active site (competitive
inhibition)32'34, but Meek and Nimmo35 have recently pro
posed that fructose-2,6-bisphosphate may inhibit the enzyme
by interacting at both the catalytic and an allosteric site
which is distinct from the AMP site. There is, however, a
general agreement that fructose-2,6-bisphosphate enhances
the sensitivity to allosteric inhibition by amp.31/32/34"36
McGrane et al34 have suggested that the binding of
fructose-2,6-bisphosphate to FBPase may bring about a
conformational change which facilitates AMP binding. The
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effect of fructose-2,6-bisphosphate on the chemical
modification of the AMP site has been studied. Pilkis et
al36 have reported that fructose-2,6-bisphosphate can almost
completely protect rat liver FBPase against desensitization
to AMP inhibition by acetylimidazole, while Pontremoli et
al32 and Gottschalk et al.33 have reported that fructose-2,6-
bisphosphate can protect rabbit liver34 and pig kidney33
FBPases against modification of the AMP site by pyridoxal-
phosphate. Han et al31 have recently found that fructose-
2,6-bisphosphate can markedly reduce the rate of
desensitization of turkey liver FBPase to AMP inhibition by
butanedione. These data strongly suggest that the binding
of fructose-2,6-bisphosphate to FBPase significantly affects
the reactivities of all three essential amino acid residues
(tyrosine, lysine and arginine) at the AMP allosteric site.
Although the inhibition of FBPase by excess substrate
(fructose-1,6-bisphosphate) was reported by Mendicino and
Vasarhley21 early in 1963, the mechanism for this inhibition
is still poorly understood. Meek and Nimmo35 have suggested
that high levels of fructose-1,6-bisphosphate may inhibit
FBPase by binding to an allosteric site (distinct from the
AMP site). They have also suggested that fructose-2,6-
bisphosphate can inhibit FBPase by binding to this
allosteric site. Han et al30 have previously reported that
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treatment of chicken liver FBPase with acetylsalicylate
desensitizes the enzyme to inhibition by excess substrate
without significantly altering the catalytic activity and
that this desensitization can be prevented if treatment with
acetylsalicylate is performed in the presence of high levels
of substrate. It is possible that acetylsalicylate may
selectively alter the "fructose-l,6-bisphosphate allosteric
site". It is noteworthy that there has been no report so
far demonstrating the binding of more than one molecule of
fructose-l,6-bisphosphate per subunit.34 Meek and Nimmo35
considered this might be only detectable at high levels of
either of the fructose bisphosphatases. They have thus
suggested that crystallographic studies may be needed to
resolve this problem.
Chemical modification of proteins is a very important
method utilized to probe protein structure and function to
determine essential amino acids present at critical sites.
Chemical modification has been used to identify important
catalytic and allosteric residues and to study the amino
acids involved in substrate and effector binding. A
chemical reagent is placed in contact with the enzyme or
protein of interest, and under specific conditions, desired
reaction occurs binding this reagent to the functional side
chain of certain reactive amino acyl residues. The
5
reaction, producing a change in a measurable property (or
properties) of the protein, can be detected and the extent
of modification thus determined. In this study, 2,3-
butanedione is used to modify arginyl residues in fructose-
1,6-bisphosphatase from chicken liver.
CHAPTER II
LITERATURE REVIEW
The existence of arginine residues has been confirmed
at the active sites of antibodies,37 alcohol dehydro-
genase,38 creatine kinase,39 erythrocyte superoxide
dismutase40 and E. coli alkaline phosphatase.41
Several dicarbonyl compounds have been used to modify
arginine. Under alkaline conditions, 1,2-cyclohexanedione
reacts with the guanido group of arginine to form a new
alpha-amino acid, 1,2-cyclohexanedione-arginine.42 The
existence of arginine at the active site of a rabbit muscle
enzyme was proven by modification of phosphoglucoisomerase
with phenylglyoxal.43 Use of butanedione to modify arginine
was first reported by Yankeelov et al.44 Butanedione is the
preferred reagent due to the mild conditions employed to
achieve modification. Yankeelov reported the use of a dimer
and trimer of butanedione to modify arginine residues of
proteins, with the most reactive polymer being the trimer.45
FBPase, a tetrameric enzyme composed of identical
subunits with molecular weights of approximately 35,000
daltons,46"48 has been modified using butanedione.
The enzyme is inhibited by AMP which is believed to
act allosterically.13'23"25'32"36'49'50 Chemical
modification studies with N-acetylimidazole,25'32'36
pyridoxal phosphate32'33 and butanedione23'24'50 have shown
that tyrosyl, lysyl, and arginyl residues all appear to be
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present at the AMP allosteric site. There is, however, a
general agreement that the presence of fructose-2,6-
bisphosphate enhances the sensitivity to allosteric
inhibition by AMP.32"36 It has been suggested that binding
of fructose-2,6-bisphosphate to FBPase brings about a
conformational change which facilitates AMP binding. 34
The effect of fructose-2,6-bisphosphate on the chemical
modification of the AMP site has been studied.
One mechanism for the modification of arginine by
butanedione was proposed by J. Riordan (see Figure 1). This
proposed mechanism involved a reaction between the guanido
group of arginine and the dicarbonyl, butanedione, in borate
buffer. Riordan reported that butanedione could first react
reversibly with the guanido group of arginine to form the
cis-diol, dihydroxyimidazoline, derivative. This
dihydroxyimidazoline derivative complexes with the borate
buffer by means of a rapid readily reversible process.51
The intermediate rearranges to a stable product which no
longer reacts with borate.52 This product is probably
formed by a pinacol-type rearrangement.53
Toi et al42 reported a similar mechanism using 1,2-
cyclohexanedione in phosphate buffer. Toi's experiments
were in phosphate buffer, demonstrating that rearrangement



















J. Riordan's proposed mechanism for the
modification of arginine by butanedione.
Guanido group of arginine and butanedione
reacts in borate buffer to form the cis-diol,
dihydroxyimidazoline derivative. The
dihydroxyimidazoline derivative complexes
with the borate buffer, the intermediate
formed rearranges to a stable product which
no longer reacts with borate.
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Frank Marcus performed amino acid analysis after
modification of FBPases with butanedione.23 Amino acid
analysis and change in physical properties of the enzyme
after modification indicated the participation of arginine
in AMP inhibition of the enzyme. Modification of FBPase
with butanedione is reported to result in the loss of two
arginyl residues per mole of enzyme subunit. J
Chemical modification of FBPases with 2,3-butanedione
was studied by two laboratories. J. Riordan studied
modification of rabbit muscle FBPase with butanedione and
concluded that FBPase has essential arginyl residues at the
AMP regulatory site, and also at the catalytic site.
Riordan reported almost complete inactivation of FBPase
after exposure to butanedione for two hours. Marcus1
studies on enzyme modification were conducted using pig
kidney and rabbit liver FBPase. Marcus reported that
arginyl residues play an essential role in both monovalent
cation activation and AMP inhibition of FBPase. Marcus
reported no change in enzyme catalytic activity after
treatment of FBPase with butanedione for three hours. Both
investigators reported loss of AMP inhibition of FBPase
after modification with butanedione. These researchers
reported conflicting data on what happens at the catalytic
site. Riordan reported complete inactivation in two hours,
where Marcus reported no change in the catalytic property
after incubation with butanedione. This laboratory wanted
10
to determine what were the effects of butanedione
modification of FBPase from a different species and if these




Purification of chicken liver enzyme. Approximately
200 grams of liver are cut into small pieces and homogenized
for two minutes at medium speed in a blender with 500 ml of
50mM Tris-HCl buffer (pH 8.0) containing l.OmM EDTA and
2.0mM cysteine. The homogenate is centrifuged for 15
minutes at 14,000 RPM. The precipitate is discarded.
Supernatant (crude extract) is transferred into a
beaker and heated in a water bath with constant stirring.
The temperature of the water bath is maintained at 85°C with
the temperature of the enzyme solution not exceeding 60°C.
When the temperature of the enzyme solution reaches 60°C the
solution is rapidly cooled in an ice bath to 20°C. The
solution is then centrifuged for 15 minutes at 14,000 RPM
and the precipitate discarded.
Fructose-l,6-bisphosphate (2mM), is added to the heat
extract, stirred and allowed to stand for five minutes.
Twenty grams of treated phosphocellulose54 is added to this
fraction, to bind unwanted proteins. The pH of the solution
then is adjusted to 6.3. This slurry is filtered twice
through a Buchner funnel by vacuum filtration. MgCl2 (2mM)
is added to the yellow liquid filtered extract, the pH is




Twenty grains of treated phosphocellulose are added to
the above fraction and the pH is adjusted to 5.2 with HC1.
Phosphocellulose is added until the enzyme activity is no
longer observed in the supernatant. The supernatant is then
filtered through a Buchner funnel and the phosphocellulose
is washed with washing buffer which consists of 0.2 M sodium
acetate buffer (pH 6.3) and 0.1 mM EDTA.
A slurry of the washed FBPase-bound phosphocellulose is
poured into a glass column, properly packed and washed with
washing buffer until absorbance at 280nm equals zero. At
this point, the enzyme is eluted with washing buffer
containing 0.1 mM AMP and 0.5 mM fructose-l,6-bisphosphate.
The eluate is collected in fractions and the enzyme activity
is measured. Fractions having high enzymatic activity are
pooled. Ammonium sulfate to 80% saturation is added slowly
to the pooled fractions and the solution is allowed to stand
15 minutes after all ammonium sulfate has dissolved. The
saturated solution is centrifuged for 15 minutes at 14,000
RPM. The protein precipitate is dissolved in 50 mM Tris
buffer( pH 7.5) containing 0.1 mM EDTA, and dialyzed three
times against two liters of the same buffer for two hours.
Enzyme Assay. FBPase activity is determined by
measuring the formation of fructose-6-phosphate
spectrophotometrically by following the reduction of
nicotine adenine dinucleotide (NAD) at 340nm in a coupled
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reaction containing excess phosphoglucose isomerase and
glucose-6-phosphate dehydrogenase.
The standard reaction mixture (1.0 ml) contains 50 mM
Tris-HCl buffer (pH 7.5), 0.1 mM EDTA, 0.2 mM NAD, 1 unit of
phosphoglucose isomerase, 1 unit of glucose-6-phosphate
dehydrogenase and a sufficient amount of FBPase in a cuvette
having a 1.0 cm path length. After incubating for one
minute at 25°C, the reaction is started by the addition of
0.1 mM fructose-l,6-bisphosphate. A unit of FBPase activity
is defined as that amount of enzyme which catalyzes the
formation of 1.0 micromole of fructose-6-phosphate per
minute per milligram of protein.
All experiments were done in the laboratory under




FBPase was purified from chicken livers as described in
the experimental section. Assays were done as described in
the experimental section at pH 7.5 and 9.2. This enzyme
exhibited higher activity at pH 7.5 indicating a neutral
enzyme.
Inhibition by adenosine monophosphate (AMP), an
allosteric inhibitor of FBPase, was demonstrated when the
enzyme was assayed in its presence (Fig. 2). A Kj for AMP
of 40 mM was observed. Inhibition by fructose-2,6-
bisphosphate, a controversial but extremely sensitive
inhibitor of FBPase was observed (Fig. 3). A Kj for
fructose-2,6-bisphosphate of 3.0 mM was observed.
Since each investigator used a different concentration
of butanedione for modification, modification at various
butanedione concentrations was observed (data not shown) to
determine the most effective concentration required for
modification. High concentrations of butanedione affect the
rate of modification. However, there is no change in the
final extent to which modification occurs. A butanedione
concentration of 20 mM, was used in all experiments.
The time course of changes in enzyme activity after
incubation of chicken liver FBPase with 20 mM butanedione in
borate buffer (pH 8.1) and assaying in the presence of AMP
and or fructose-2,6-bisphosphate is shown in Figure 4. The
14
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FIGURE 2. AMP inhibition of native chicken liver
FBPase, specific activity, 5.75 mmole min"1
milligram
-1 The AMP inhibited enzyme was
assayed as described in the experimental
section, except the assay buffer contained





native chicken liver FBPase. Enzyme was
assayed as described in the experimental















with 20 mM butanedione. Enzyme assays were
done at specific time intervals during
modification. The assays were done in assay
buffer containing fructose-2,6-bisphosphate
(F-2/6-P2)/ AMP (AMP) and standard assay
buffer (no additions).
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native FBPase in the presence of AMP and fructose-2,6-
bisphosphate exhibited inhibition of 56 and 62%,
respectively. When treated with butanedione, the
inhibitions were relieved. Enzyme modified with butanedione
and assayed using the standard assay system (described in
the experimental section) showed an increase in the relative
activity of FBPase by 70 per cent in two hours. This is
probably due to substrate inhibition being relieved since
0.1 mM substrate is used in the assay mixture. The observed
AMP and fructose-2,6-bisphosphate inhibitions were abolished
after FBPase was treated with butanedione for two hours.
These results may indicate a definite change at the
allosteric site(s) upon modification with butanedione.
Protection studies were done to further explain what
occurs upon modification of FBPase with butanedione. The
time course of FBPase activity during incubation of the
enzyme with 20 mM butanedione in borate buffer containing
50 mM AMP is shown in Figure 5. Assays were done in the
standard assay buffer with 50 mM AMP added. Enzyme inhibi
tion of 56% by AMP is retained when FBPase is modified with
butanedione in the presence of AMP. The catalytic activity
of the enzyme still increases 70% above the control enzyme
activity indicating no inhibition at the catalytic site.
These results suggest that AMP in the modification mixture






FIGURE 5. Protection study using AMP. FBPase, specific
activity 5.75 mmole min"1 milligram"1 was
modified with 20 mM butanedione in the
presence of 50 mM AMP. The modified enzyme
was assayed in buffer containing AMP (AMP)
and buffer with no additions (Control). Also
included is FBPase modified with butanedione
alone and assayed in the presence of AMP
(Modified AMP).
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Substrate (fructose-1,6-bisphosphate) protects the
enzyme from modification with butanedione (Figure 6). The
presence of substrate in the modification mixture gives 27%
relief of the fructose-2,6-bisphosphate inhibition and the
activity increases from 38% to 65%. An increase in
substrate concentration results in complete retention of
fructose-2,6-bisphosphate inhibition. The catalytic
activity of the enzyme does not increase 70% above the
control as demonstrated when the enzyme is modified in the
presence of butanedione alone, indicating that substrate
inhibition is not relieved when the enzyme is modified in
the presence of butanedione and substrate. This protection
study demonstrates that substrate protects the catalytic and
fructose-2,6-bisphosphate sites.
Butanedione modification in the presence of fructose-
2,6-bisphosphate is shown in Figure 7. Total retention of
inhibition has been observed in the presence of higher
concentrations of fructose-2,6-bisphosphate. Fructose-2,6-
bisphosphate inhibition is partially relieved. Modification
in the presence of butanedione and fructose-2,6-bisphosphate
retains high substrate inhibition and relieves AMP inhibi
tion. There is a slight relief of fructose-2,6-bisphosphate








Protection study using fructose-1,6-
bisphosphate (substrate). FBPase was
modified with 20 mM butanedione in the
presence of substrate. The enzyme was
assayed in the presence of fructose-2,6-











FIGURE 7. Protection study using fructose-2,6-
bisphosphate. FBPase was modified with 2 0 mM
butanedione in the presence of 3 mM fructose-
2,6-bisphosphate. The enzyme was assayed in
the presence of fructose-2,6-bisphosphate




The data presented in this thesis agree with that
presented by Marcus and Riordan on the presence of arginine
at the AMP allosteric site of chicken liver FBPase as seen
in rabbit liver, rabbit muscle and pig kidney FBPase. There
is, however, a difference in the catalytic response of the
enzyme to butanedione modification. Riordan reports
complete loss of catalytic activity after modification and
Marcus reports no change in the catalytic activity after
butanedione modification. Some of these discrepancies could
be due to experimental conditions, the difference in enzyme
preparation, or the use of different species.
An increase in catalytic activity was observed by this
laboratory and it has been concluded, from protection
studies, that the increase in catalytic activity after
butanedione modification is due to relief of inhibition by
high substrate concentration. The protection studies done
in our laboratory, which involved modification of FBPase
with butanedione in the presence of AMP, fructose-1,6-
bisphosphate and fructose-2,6-bisphosphate suggest
arginine's involvement in substrate and effector binding.
When FBPase is modified with butanedione and fructose-
1,6-bisphosphate (substrate), an increase in catalytic
23
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activity was not observed. Substrate binds to its enzyme
site(s) during modification, preventing reaction with
butanedione, therefore maintaining high substrate
inhibition.
Additional information presented in this paper and not
discussed by Marcus or Riordan is FBPase inhibition by
fructose-2,6-bisphosphate. Fructose-2,6-bisphosphate
inhibition is not clearly understood but it is still being
investigated. Modification with butanedione alone abolishes
this inhibition. The addition of fructose-2,6-bisphosphate
or substrate to the modifying mixture retains the inhibition
showing that fructose-2,6-bisphosphate and substrate protect
a portion of the enzyme from butanedione modification. We
also see that F-2,6-P2 is a very potent inhibitor that
affects AMP inhibition and substrate inhibition.
Inconsistencies in FBPase response to butanedione modi
fication have been observed. These variations may be partly
attributed to two recently discovered phenomena. First,
divalent cation requirement for activity has been reported
by several researchers. However, recently Han and co-
workers have noticed a drastic change in FBPase response to
Mn2+ activity during and after extraction of the enzyme
(manuscript in preparation, personal communication). A
paper discussing these details is in preparation. Secondly,
there is a different response to modification by butanedione
in different lighting conditions. Butanedione•s sensitivity
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to light is known and precautions to avoid storing the rea
gent in light were taken. However, depending on whether the
reaction of the enzyme with butanedione is done in the
presence of light or in darkness, different reactions were ob
tained due to conditions of the incubation mixture. Butane
dione has been classified as a photosensitizing agent.55
Photodestruction of several amino acid residues occurs with
butanedione in the presence of normal laboratory light, UV
light and oxygen and is inhibited in anoxic media or in the
presence of azide.55 Experimental conditions for consistent
modification must be clearly controlled to get the desired
reaction. The data presented in this thesis are reproducible
when the lighting conditions within the laboratory are con
stant. We used normal fluorescent lighting (see Experi
mental) .
The present studies of FBPase have been beneficial. The
significance of this study is that it suggests AMP and
fructose-2,6-bisphosphate sites that are sensitive to
butanedione modification, presumably contain the arginyl
residues. If an inert carrier that can react specifically
with arginyl residues is identified, then chicken liver FBPase
can be attached to these carriers by its arginyl residues at
the AMP and fructose-2,6-bisphosphate sites. Enzyme
immobilization studies are being conducted in this laboratory
and characterization of the enzyme is essential for specific
attachments of the enzyme to the inert carriers.
CHAPTER VI
CONCLUSION
Modification of chicken liver FBPase results in loss of
AMP inhibition, fructose-2,6-bisphosphate inhibition and an
increase in catalytic activity. The increase in catalytic
activity is attributed to relief of substrate inhibition
after modification with butanedione.
AMP allosterically inhibits chicken liver FBPase as is
seen in the enzyme from other sources. The binding site of
fructose-2,6-bisphosphate to FBPase is controversial.
Fructose-2,6-bisphosphate does, however, protect FBPase's
catalytic site from modification with butanedione by
maintaining high substrate inhibition as well as protecting
F2,6-P2 inhibition. Further studies will have to be done to
determine if fructose-2,6-bisphosphate binds at the
catalytic site or some other site on the enzyme distinct
from the catalytic site.
The use of butanedione for chemical modification of
proteins may be effective in identifying arginyl residues at
specific sites. The conditions of this modification should
be clearly outlined and followed to get reproducible
results. Since there has been research to show that in the
presence of light, several amino acids can be affected by
sensitized butanedione, the modification of arginyl residues
due to butanedione remains to be unequivocally proven.
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